The Lagos University Teaching Hospital (LUTH), in collaboration with the Sickle Cell Foundation Nigeria (SCFN), has launched a high-quality bone marrow transplant program aimed at curing sickle cell disease to meet international standards.

In a joint statement by LUTH’s Chief Medical Director, Prof. Wasiu Adeyemo, and SCFN’s National Director, Dr. Annette Akinsete, the significance of this initiative was highlighted, especially given Nigeria’s status as having the highest burden of sickle cell disease globally. The statement emphasized the severe complications faced by affected individuals, including reduced life expectancy and organ damage, underscoring the need for improved care.

The newly established program builds on earlier efforts, including a post-transplant clinic initiated in 2019 to support patients who previously sought treatment abroad. While therapies like chronic blood transfusions and hydroxyurea have improved survival rates for children, adult patients still face challenges, particularly those with severe forms of the disease. Bone marrow transplant, which has become a recognized cure, requires careful management and a multidisciplinary approach.

Currently, the first patients are undergoing treatment at LUTH, following a comprehensive preparatory regimen of blood transfusions, chemotherapy, and infection prevention measures. With a dedicated team, including experts from both local and international institutions, the program aims to provide a viable treatment option within Nigeria, alleviating the hardships faced by families seeking care abroad.